TELO
Telomir Pharmaceuticals, Inc.1.4000
-0.0200-1.41%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
48.13MP/E (TTM)
-Basic EPS (TTM)
-0.37Dividend Yield
0%Recent Filings
8-K
Telomir-Zn kills TNBC cells
Telomir Pharmaceuticals announced preclinical data on February 17, 2026, showing Telomir-Zn induced near-complete mortality in EGFR-high TNBC cells and partial reductions in other subtypes at 72 hours. Iron-rescue experiments confirmed an iron-dependent mechanism, not nonspecific toxicity. No adverse effects seen in prior GLP tox studies. Telomir eyes Q1 2026 IND filing.
8-K
Telomir-Zn metal modulation data
Telomir Pharmaceuticals unveiled preclinical data on February 5, 2026, showing Telomir-Zn rapidly boosts intracellular zinc while slashing labile iron in cells—without toxicity. This metal swap curbs oxidative stress, bolsters epigenetics, and guards mitochondria, hitting shared cancer-aging drivers. Data powers Q1 2026 IND filing. Preclinical pipeline advances briskly.
8-K
Nasdaq compliance warning issued
Telomir Pharmaceuticals received a Nasdaq notice on January 8, 2026, for failing to hold its annual shareholder meeting within 12 months of fiscal year-end, violating Listing Rule 5620(a). No immediate delisting; must submit a compliance plan by February 23. Company plans prompt meeting post-SEC proxy review. Compliance hinges on Nasdaq approval.
8-K
Telomir-1 curbs TNBC tumors
Telomir Pharmaceuticals reported preclinical results showing Telomir-1 significantly reduced tumor growth and metastases in two aggressive TNBC zebrafish models, effective alone or with paclitaxel where chemo failed. Responsive tumors mirror 40–60% of TNBC cases; a resistant model matched 15–25%. Telomir-1 targets metal-dependent pathways. Findings guide patient selection for trials. Preclinical data varies by model.
8-K
CEO incentive awards approved
Telomir Pharmaceuticals approved CEO Erez Aminov a $400,000 2025 STI payout for operational execution and financing wins. It added a $150,000 contingent bonus on future FDA IND acceptance for Telomir-1, a 3% advisory award on the strategic TELI acquisition, and $500,000 base salary from January 1, 2026. Awards tie pay to key milestones. TELI deal remains pending.
ATHA
Athira Pharma, Inc.
3.88+0.03
FBLG
FibroBiologics, Inc.
0.24-0.02
GERN
Geron Corporation
1.34+0.01
IGC
IGC Pharma, Inc.
0.34+0.00
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
LGVN
Longeveron Inc.
0.55+0.00
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MTSR
Metsera, Inc.
70.50-0.25
TLX
Telix Pharmaceuticals Limited
8.34-0.29
VIR
Vir Biotechnology, Inc.
6.48-0.24